Products
Osocimab Biosimilar Monoclonal Antibody (Factor XI) for Research
Pre-Made Osocimab biosimilar, Whole mAb, Anti-F11 Antibody: Anti-FXI/PTA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-413-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Osocimab biosimilar, Whole mAb, Anti-F11 Antibody: Anti-FXI/PTA therapeutic antibody |
| INN Name | Osocimab |
| Target | F11 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 6hhc:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Bayer HealthCare |
| Conditions Approved | na |
| Conditions Active | Venous thromboembolism |
| Conditions Discontinued | Arterial thrombosis;Venous thrombosis |
| Development Tech | na |
About target - F11
1. Protein Cytochrome P450 4F11
2. Gene CYP4F11
3. Organism Homo sapiens (Human)
Function
A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins) (PubMed:24138531, PubMed:15364545, PubMed:18065749).
Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:15364545, PubMed:18065749, PubMed:24138531).
Catalyzes with high efficiency the oxidation of the terminal carbon (omega-oxidation) of 3-hydroxy fatty acids, such as 3-hydroxyhexadecanoic and 3-hydroxyoctadecanoic acids, likely participating in the biosynthesis of long-chain 3-hydroxydicarboxylic acids (PubMed:18065749, PubMed:19932081).
Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation (PubMed:24138531).
Metabolizes with low efficiciency fatty acids, including (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) and its oxygenated metabolite 8-hydroxyeicosatetraenoic acid (8-HETE) (PubMed:15364545, PubMed:19932081).
Catalyzes N- and O-demethylation of drugs such as erythromycin, benzphetamine, ethylmorphine, chlorpromazine, imipramine and verapamil (PubMed:15364545).
